Nan Fung Life Sciences and Novo have taken part in a series B round for Stanford's immuno-oncology drug developer Bolt Biotherapeutics.

Bolt Biotherapeutics, a US-based cancer therapeutics spinout of Stanford University, closed a $54m series B round yesterday featuring pharmaceutical firm Novo and Nan Fung Life Sciences, a subsidiary of property development group Nan Fung.
The round was led by Pivotal BioVenture Partners, the life science investment vehicle set up by Nan Fung, and included investment firm Vivo Capital.
Founded in 2015, Bolt is developing therapies that will fight cancer by using immune-stimulating antibody conjugates (ISACs) to reinvigorate the body’s immune system and heat up cold tumours so they can be detected by the immune system.
In addition to advancing the company’s lead conjugate into clinical trials, funding from the round will also be invested in its technology platform. Bolt’s technology is based on research by co-founder Edgar Engleman, professor of pathology and of medicine (immunology and rheumatology).
Peter Moldt, a partner at Novo Ventures who is also…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?